Transplantation of allogeneic CD34
؉ blood cells in leukemia or lymphoma patients at high risk of GVHD Allogeneic blood cell transplantation (BCT) is a fascinating example of adoptive immunotherapy, in which the graftversus-leukemia (GVL) effect contributes to the cure of a proportion of leukemias and other malignancies. However, its applicability is limited by graft-versus-host disease (GVHD). T cell depletion is an efficient way to prevent, or reduce the incidence and severity of GVHD, although this efficacy is associated with a higher incidence of relapses and graft failures. A decade ago, complement-mediated cytotoxicity was widely used for T cell depletion of bone marrow grafts. The use of these techniques is now restricted by new regulations in cell therapy facilities, and modern biomedical devices are increasingly substituted: the prototypical examples are CD34 ϩ cell selection devices, that indirectly achieve a very efficient T cell depletion.
1,2 Other developments in medical technologies contribute to a renewed interest in T cell depletion: collection of allogeneic aphereses from mobilized healthy donors produces grafts that are enriched in hematopoietic progenitors and stem cells when compared with bone marrow grafts. 3, 4 Thus, the combination of allogeneic blood cells with CD34 ϩ cell selection offers an attractive strategy for T cell depletion, with the expectation that the risk of graft failure may be overcome by the reinfusion of large numbers of hematopoietic progenitors. In addition, because donor lymphocyte infusions are able to induce new remissions in patients who relapse after allogeneic transplantation, there is hope that prophylactic infusions of donor lymphocytes (such as cells collected in the so-called 'CD34 − fraction') may reduce the frequency of leukemic relapses following T cell-depleted allogeneic transplantation.
In two recent reports, 5, 6 the most recent in this journal 6 Urbano-Ispizua et al describe their important experience in 62 patients with early stage leukemias transplanted with CD34 ϩ blood cells obtained from HLA-matched siblings. The conditioning regimens that they used were standard, and most patients received cyclosporin A and steroids as GVHD prophylaxis. While the number of infused CD3 ϩ cells was below 0.4 × 10 6 /kg, they report a full and rapid engraftment, the nearly total absence of GVHD and no increase in relapse rate. Our own experience has produced less favorable results. Fourteen patients at risk of developing aGVHD (age у40 years: n = 11, or advanced disease: n = 9) were prepared after informed consent with cytoxan (120 mg/kg) and TBI (12 Gy in six fractions over 3 days) ( Table 1) . Three patients had an additional dose of melphalan, 140 mg/m 2 . GVHD prophylaxis consisted of cyclosporin A, methotrexate (MTX) (days 1, 3 and 6) and one dose of anti-thymocyte globulin (ATG) for the eight first patients. Because we observed that cell selection consistently resulted in the reinfusion of less than 0.1 × 10 6 CD3 ϩ cells/kg, GVHD prophylaxis was reduced (MTX only: n = 2) and eventually suppressed (n = 4). Donors were mobilized with rhG-CSF (Neupogen, Amgen, Thousand Oaks, CA, USA), 10 g/kg daily, for 5 days. Two patients received unselected cells, because of poor mobilization of their healthy sibling, and both patients died of GVHD. For the 12 other donors, a median number of 9.97 (5.2-26.2) CD34 ϩ cells/kg, and 333.1 (52.6-744.3) CD3 ϩ × 10 6 /kg were collected with a median of 2 (2-3) aphereses. CD34 ϩ cell selection was performed using the Isolex 300i biomedical device (Nexell, Irvine, CA, USA), according to the manufacturer's recommendations (immuno-magnetic method). A median of 4.6 × 10 6 adsorbed CD34 ϩ cells/kg (2.19-9.53), and of 0.17 × 10 6 CD3 ϩ cells/kg (0.04-0.67) were obtained after selection, and infused into the patients. The median loss of CD34 ϩ progenitors was 46.1% (68.6%-15.6%), and the median T cell depletion was 3.4 log (2.75-5.51).
The outcome for these high risk patients is uniformly poor: in addition to the two patients who received unselected cells, all 12 patients died at a median of 75 days after transplantation (9-520). One patient died on day 9 of bacterial sepsis. Four patients experienced graft failure: three of them did not show any evidence of engraftment, and one had a secondary graft rejection, coincidental with CMV disease and treatment with DHPG (all patients were checked twice weekly for CMV antigenemia, and preemptively treated); these observations were not associated with the lowest numbers of hematopoietic progenitors, or of infused CD3 ϩ cells. Four patients experienced grade II to IV aGVHD, which was the cause of death in three cases. The two patients who had grade IV aGVHD were 45 and 50 year old, were infused with 0.044 and 0.065 × 10 6 CD3 ϩ cells/kg, and did not receive any post-graft immunosuppression. Three patients relapsed at 31, 60 and 330 days post- transplant, and ultimately died. Two of them presented prior evidence of GVHD (aGVHD: n = 1; cGVHD: n = 1). Finally, two patients received donor lymphocyte infusions, one because of relapse, and one as a prophylactic measure (this patient was transplanted for a refractory malignancy): the first one died of active disease, and the second one of severe GVHD. The dramatic differences between Urbano-Ispizua's results 6 and ours may in part be related to patients' characteristics. Four of 12 patients in our group, and two of 62 patients reported by Urbano-Ispizua et al 6 experienced graft failure. The apparently higher incidence in our study may in part be explained by more advanced diseases in our patients since the probability of rejection is higher for these patients, especially those with transformed CML or with MDS. In addition, five of seven engrafted patients who were studied had mixed chimerism, an observation that is clearly different from what was reported in patients transplanted with unmanipulated grafts. Three patients have relapsed in our study, but again were at high-risk of relapse because of the status of their diseases. In Urbano-Ispizua's series, the short follow-up prevents a firm conclusion regarding the control of the disease by allogeneic transplantation. Finally, there is a major difference between the two studies in the incidence of severe aGVHD. Three of our patients died from primary aGVHD, while four patients developed grade II, one patient developed grade III, and no patient developed grade IV aGVHD in Urbano-Ispizua's series. It must be pointed out that one patient received the highest dose of CD3 ϩ cells of our cohort, and that the two others did not receive post-graft immunosuppression. These results are however concordant with previous publications. 2 In conclusion, our data confirm that CD34 ϩ cell selection is an effective and relatively reproducible method of T cell depletion. However, the use of these biomedical devices associated with the substitution of allogeneic blood cells to allogeneic bone marrow cells did not significantly improve the outcome of allogeneic progenitor cell transplantation for a group of patients that were at high risk of developing aGVHD. These observations confirm that the physiopathology of GVHD involves multiple factors, some of which are related to the quality of the graft, some of which are related to the recipient, and some of which are related to the preparative regimen. T cell depletion associated with pharmacological post-graft immunosuppression may be efficient in preventing GVHD in young patients, transplanted early in the course of their disease; however, a benefit in terms of survival has not yet been demonstrated. T cell depletion is likely to be less effective in older patients, with more advanced diseases, especially in the absence of post-graft pharmacological prophylaxis of GVHD. Despite the high number of infused CD34 ϩ cells, we observed several cases of graft failure. While they may result from several factors, these observations raise questions about the principle of CD34 ϩ cell selection, especially since recent publications suggest that a proportion of human stem cells cells may be
CD34
− . [7] [8] [9] The consequences of graft manipulation in terms of disease control cannot be evaluated until transplantrelated mortality is significantly improved.
